NYSE •
Healthcare •
Biotechnology •
Quote as of 08/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization79.98 mln
Float27.70 mln
Earnings Date08/18/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
11.00
Transformational upside
Relative Strength
80
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-271
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Annovis Bio is a Pennsylvania-based medical research company focused on developing treatments for brain diseases such as Alzheimer's, Parkinson's, and dementia. Its most advanced drug, Buntanetap, is currently being tested in late-stage clinical trials for both Alzheimer's and Parkinson's disease. The company also has two other drug candidates at various stages of testing, targeting traumatic brain injury, stroke, and cognitive decline. Founded in 2008, Annovis Bio continues to build a pipeline aimed at slowing or reversing the progression of neurological conditions.
